ARB's FY25 loss blew out to NZ$21.5m as H2 turned sharply negative

What changed

Revenue fell 6.6% to NZ$63.2m from NZ$67.7m, but the damage was concentrated below the gross line. Gross margin contracted 665bps to 28.8% (from 35.5%) as cost of sales rose to NZ$45.0m against a smaller revenue base. The operating loss widened to NZ$20.8m from NZ$0.2m, PBT deteriorated to a NZ$22.5m loss from NZ$1.6m, and NPAT swung to a NZ$21.5m loss from a NZ$0.2m loss. Operating cash flow fell 76.9% to NZ$2.7m, cash declined to NZ$3.5m, and gross borrowings rose to NZ$24.4m (from NZ$20.0m), lifting net debt to NZ$20.9m from NZ$14.4m. Equity dropped 16.2% to NZ$124.6m, essentially absorbing the year's loss.

What matters

• PBT is the cleaner read. NPAT appears even worse than PBT because the group still booked a NZ$1.0m tax expense against a NZ$22.5m pre-tax loss. PBT deteriorated by NZ$20.9m year on year — the core operating result, not the tax line, is where the damage sits.
• H2 is where the loss crystallised. HY25 delivered NZ$13.2m of revenue (20.9% of full year) and a near-breakeven NPAT of -NZ$0.1m. That implies H2 carried NZ$50.0m of revenue but a NZ$21.4m loss — i.e. the higher-revenue second half was where margin, and very likely a charge or write-down, hit. The release excerpts do not name the specific driver.
• Balance sheet weakened on two fronts. Cash fell NZ$2.1m while gross debt rose NZ$4.4m, and inventory built to NZ$38.4m (311.7 days, up from 293.2). The business absorbed working capital and drew debt to fund a year in which FCF pre-lease turned negative at -NZ$5.1m (from +NZ$5.1m).

Expectations

No forward-work, guidance, or quantitative targets were supplied. The one shape signal — HY25 being just 20.9% of full-year revenue — confirms a heavily second-half-weighted business (consistent with the cone-harvest and seedling seasonality referenced in the HY context). That seasonality normally argues for a strong H2, so the fact that H2 carried the entire NZ$21.4m loss despite NZ$50m of revenue is the key anomaly a reader should want explained. The release as supplied does not support any view on FY26 recovery; it documents a deterioration but not its cause or persistence.

Quality of result

Low. The NZ$2.7m of operating cash flow was insufficient to fund NZ$7.8m of capex (12.3% of revenue, up from 9.7%), and the gap was closed with incremental debt. Cash conversion deteriorated materially even allowing for the loss: cash flow from operations before working capital movements was NZ$10.8m versus NZ$11.6m prior, so the ~NZ$8m working-capital drag — led by inventory build of NZ$3.3m — explains most of the OCF collapse. Receivable days fell (1.7 from 7.6), which helped, but not enough to offset inventory. Equity shrank almost exactly in line with the reported loss, so there is no suggestion of a one-off non-cash accounting charge masking a better cash outcome; the result looks real rather than timing-driven, and the trajectory is clearly negative.

Unresolved

• What drove the H2 step-down: impairment, inventory write-down, pricing, or volume shortfall? The supplied excerpts do not identify the specific line item.
• Why tax expense remained positive against a large pre-tax loss — is deferred-tax asset recognition being restricted?
• Inventory days of 311.7 on a NZ$38.4m book: is any of this at risk of write-down in FY26?
• Covenant headroom and committed facility size given gross debt rose to NZ$24.4m against only NZ$3.5m of cash.
• Whether management has signalled any cost, capex, or capital-structure response — none is disclosed in the supplied material.

This briefing cannot assess the operational cause of the H2 loss, management's outlook, or covenant/liquidity adequacy, because none of those are contained in the supplied extraction data.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.